Momendol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Momendol

Property Description
Active Ingredient Naproxen Sodium
Form Film-coated Tablets
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic (Propionic Acid Derivative)

The Pharmaceutical Identity of Momendol: Defining its Class and Form

Momendol is a proprietary medicinal product whose active substance is Naproxen Sodium. It is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a group of medications widely used to target both pain and inflammation. This medication is prepared for oral administration and is typically marketed as an Over-the-Counter (OTC) product in the form of small film-coated tablets. Its classification as an NSAID establishes its core pharmacological activity. Naproxen Sodium is clinically recognized for its sustained action profile compared to shorter-acting analgesics, making it a suitable choice for conditions requiring relief over a longer period.

Composition: What is Naproxen Sodium?

The sole active ingredient in Momendol is Naproxen Sodium, a compound that chemically belongs to the family of Propionic Acid Derivatives. The choice of the sodium salt form is a key feature, as it is engineered for enhanced solubility and faster absorption from the digestive tract compared to the standard naproxen acid. Once absorbed, Naproxen Sodium functions as a Cyclooxygenase (COX) Inhibitor to exert its symptomatic effects. The final tablet formulation includes necessary excipients, which are non-active pharmaceutical grade fillers and binding agents essential for creating the solid dosage form.

General Purpose: What Momendol is Designed to Relieve

The general purpose of this medication is to provide effective, simultaneous relief from the triad of discomfort: pain, inflammation, and fever. The drug achieves this by having three key high-level actions: analgesic (pain-relieving), anti-inflammatory (reducing swelling and heat), and antipyretic (fever-reducing). Drugs in this class share a common action in providing anti-inflammatory and analgesic effects. This comprehensive approach makes Momendol a form of symptomatic treatment, addressing the physical manifestations and discomfort arising from inflammatory processes. It operates by blocking the generation of the natural chemicals (prostaglandins) that trigger these symptoms, a fundamental mechanism central to all NSAID pharmacology.

What side effects are possible with Momendol ?

Possible Side Effects and Safety Information: Momendol

Momendol, containing naproxen sodium, is classified as a non-steroidal anti-inflammatory drug (NSAID) and is associated with officially documented safety warnings common to this class. All use must adhere strictly to the recommended duration and dosage to minimize risk.

Serious Adverse Reactions and Warnings

Regulatory documents emphasize two primary risks:

  • Cardiovascular Thrombotic Events: NSAIDs, including naproxen, increase the risk of serious, potentially fatal, cardiovascular thrombotic events such as myocardial infarction (heart attack) and stroke. This risk may be increased with higher doses or prolonged use and is a major restriction for use in the peri-operative setting of coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Events: NSAIDs carry an increased risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time without warning symptoms and can be fatal. This risk is greater in the elderly population.

Commonly Reported Adverse Reactions

Commonly observed side effects typically involve the Gastrointestinal System (e.g., dyspepsia, nausea, heartburn) and the Nervous System (e.g., dizziness, headache, drowsiness).

Population-Specific Restrictions and Contraindications

Momendol is contraindicated in patients with a history of allergic-type reactions (e.g., asthma, hives) to aspirin or other NSAIDs, active gastrointestinal bleeding or peptic ulcers, severe heart failure, severe renal impairment, or severe liver impairment. Use is also contraindicated during the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus and potential delivery complications. Older adults are advised to use the lowest effective dose for the shortest possible duration due to increased sensitivity to adverse effects.

Overdose and Emergency Response

The official regulatory documentation for Naproxen Sodium (the active substance in Momendol) outlines specific manifestations and mandatory emergency procedures in case of overdose.

Overdose exposure may present with distinct signs, primarily involving the Gastrointestinal System (e.g., nausea, vomiting, stomach pain, heartburn) and the Central Nervous System (e.g., drowsiness, dizziness, confusion, severe headache, or tinnitus).

Potential severe outcomes that are formally documented include life-threatening systemic complications such as gastrointestinal bleeding, ulceration, and perforation. Neurological events like seizures and coma, as well as acute kidney failure and metabolic acidosis, are also cited as possible severe consequences. Older adults and individuals with pre-existing kidney or liver conditions are explicitly noted to be at an increased risk for severe manifestations.

The required management protocol is strictly symptomatic and supportive, as regulatory agencies state there is no known specific antidote. It is a mandatory requirement to seek immediate medical attention or contact a Poison Control Center right away if an overdose is suspected. Urgent medical help must be sought if severe symptoms, such as black or bloody stools, vomiting material that resembles coffee grounds, or seizures, become apparent. Continuous hospital monitoring of vital signs and laboratory parameters is formally described in management guidelines.

Therapeutic Uses of Momendol

Momendol is generally applied across domains where additional symptomatic support is needed, primarily for symptoms related to inflammatory or irritative states. The active ingredient, Naproxen Sodium, is commonly used in these therapeutic areas; the medication is relevant in clinical settings marked by increased discomfort or tension and contributes to improved comfort during symptomatic periods.

It is commonly used across conditions presenting with acute episodes and heightened symptoms, such as musculoskeletal pain (sprains, strains, tendinitis, bursitis), episodic acute pain (headache, toothache), primary dysmenorrhea (menstrual cramping), and for managing fever. This supportive therapeutic benefit helps ease the overall symptom load and may assist with managing difficult episodes.

Quick Fact: Relief is commonly used to help with Inflammatory Discomfort and Acute Episodic Pain.

Momendol is relevant when short-term symptomatic assistance is needed, helping to moderate distressing manifestations and assists with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. DailyMed Naproxen Sodium Label

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Momendol — Official Regulatory Information

The eligibility for Momendol, which contains the active ingredient Naproxen Sodium, is strictly defined by regulatory documents, focusing on age, organ function, and pre-existing conditions.


Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents over 16 years of age (per Momendol SmPC).
Populations for whom use is contraindicated Patients with severe heart, renal, or liver failure; active or recurrent peptic ulcers or GI bleeding; or a known hypersensitivity to any NSAID or aspirin. The medicine is contraindicated in children under 12 years.
Pregnancy and lactation eligibility status Contraindicated during the Third Trimester of Pregnancy and while breastfeeding.
Eligibility-related restrictions Use is restricted in the elderly and patients with mild to moderate renal impairment, who must not exceed a specified maximum daily dose. Use is not recommended for women attempting to conceive.

Official eligibility statements:

  • Momendol is contraindicated in children under 12 years and in patients with severe organ failure or GI disease history.
  • Use is restricted in elderly patients and those with mild to moderate renal impairment, who have a lower daily dose limit.

Connection to the overall eligibility profile The regulatory documents establish absolute contraindications based on severe disease states and hypersensitivity risks. Eligibility for approved age groups is subject to conditional restrictions, ensuring use is limited or avoided in high-risk groups, such as the elderly, children under 12, and women in late pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation confirms that the active ingredient, Naproxen Sodium, has documented interaction patterns primarily concerning an additive risk for bleeding and interference with renal function. All interaction information below is based strictly on government-issued prescribing labels.


Documented Pharmacodynamic and Exposure Interactions

Interacting Substance/Class Documented Interaction Outcome Classification Focus
Anticoagulants (e.g., Warfarin) / SSRIs Increased risk of serious bleeding events and gastrointestinal ulceration. Additive Risk
Corticosteroids Increased risk of gastrointestinal bleeding and ulceration. Additive Risk
ACE Inhibitors / ARBs / Diuretics May diminish the antihypertensive or natriuretic effect of these co-administered drugs. Reduced Efficacy
Lithium / Digoxin / Methotrexate Can increase the serum concentration of the co-administered drug, raising the risk of toxicity. Increased Exposure
Probenecid Increases the plasma concentration and prolongs the half-life of Naproxen. Reduced Clearance

Restrictions and Administration Considerations

Co-administration with analgesic doses of other NSAIDs is not generally recommended. Naproxen Sodium is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Taking the medicine with food may delay its rate of absorption. Consumption of three or more alcoholic drinks daily is noted as increasing the risk of gastrointestinal bleeding. Monitoring is specified for the elderly, volume-depleted patients, or those with renal impairment when co-administered with ACE Inhibitors or ARBs, due to the risk of renal function deterioration.

Mechanism of Action

The mechanism of Momendol (Naproxen Sodium) is defined by its targeted action on biochemical pathways, specifically through the modulation of enzyme activity and subsequent control of key signaling mediators.


Molecular Targeting of the Cyclooxygenase (COX) Pathway

The drug acts primarily as a reversible competitive inhibitor of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By competing with arachidonic acid for the enzyme's active site, this mechanism suppresses the initial molecular step in the synthesis of prostaglandins and thromboxanes. This action modulates key pathways associated with heightened physiological responses, affecting the subsequent physiological responses.


Modulation of Inflammatory and Central Signaling

The suppression of prostaglandin synthesis initiates a downstream cascade that affects both the periphery and the central nervous system. Peripherally, the reduced availability of prostaglandins decreases the sensitization of pain receptors (nociceptors), resulting in an altered intensity of nociceptive signaling. Centrally, the mechanism specifically blocks the formation of fever-inducing prostaglandins ( PGE2) in the hypothalamus, facilitating the restoration of the body’s temperature set point.


Kinetics and Mechanistic Limitations

The formulation as a sodium salt enhances the drug's solubility, facilitating rapid systemic absorption that promotes the quick saturation of the COX targets and a rapid initiation of the enzyme-blocking effect. However, the drug's mechanism is fundamentally limited to processes driven by the COX pathway and cannot modulate pathways dependent on non-eicosanoid transmitters.

Dosage and Administration Information

How to Use Momendol: Administration Guidelines

Momendol, containing Naproxen Sodium 220 mg, is administered according to a structured protocol for short-term symptomatic relief. The route for the film-coated tablets or capsules is oral.


Standard Dosing and Frequency

Use is based on a unit dose of 220 mg. Administration requires maintaining specific time intervals and respecting an absolute daily maximum. The smallest effective dose should be used for the shortest duration necessary.

Dosing Parameter Instruction (Adults)
Initial Dose 220 mg (1 tablet). An optional loading dose of 440 mg (2 tablets) may be taken in the first hour.
Subsequent Dose 220 mg (1 tablet) every 8 to 12 hours.
Maximum Total Daily Dose 660 mg (3 tablets) in any 24-hour period.

Administration Context and Duration Limits

The tablets or capsules must be swallowed whole with a full glass of water. While the medication may be taken without regard to meals, administration with food or milk is permitted if the user experiences stomach upset; however, this may delay the rate of absorption.

There are strict time constraints for self-treatment: the medicine should not be taken for pain relief for more than 10 days or for fever reduction for more than 3 days unless otherwise directed.

Population-Specific Use

Dosage adjustments are specified for certain populations. Use is not permitted in children under 12 years without professional direction. For older adults (65 years and over), the total daily dose should not exceed 440 mg (2 tablets) in 24 hours.

Recent Clinical Evidence

Research evidence / Overview of studies for Momendol

The evidence base for Naproxen Sodium, the active ingredient in Momendol, has been examined through various high-quality research methods, including short-term randomized controlled trials (RCTs), systematic reviews, and pooled data analyses.


Evidence for Studies of Short-Term Acute Pain

Research exploring how symptoms change over time in acute pain has been a consistent focus. Studies have primarily been conducted during periods of increased symptom activity, utilizing RCTs to examine patient-reported experiences in populations of adults experiencing acute, disruptive episodes, such as headache, toothache, and post-operative pain models.

In these research scenarios, studies monitored outcomes related to physical discomfort using specific measurements like the Sum of Pain Intensity Differences (SPID). Findings report patterns observed in the studies related to data collected on pain scores over short, defined time intervals, contributing to the broader evidence landscape for short-term symptom management.


Evidence for Studies in Musculoskeletal and Inflammatory Conditions

Naproxen Sodium was studied for use in conditions associated with acute or disruptive episodes of musculoskeletal pain, such as sprains, strains, and minor pain from conditions like mild osteoarthritis. The studies explored outcomes related to symptoms in conditions marked by functional limitations and periods of heightened symptom activity.

Researchers specifically examined outcomes related to daily functioning and activity level. Studies monitored how symptoms were reported in the observed populations, and findings report patterns related to data collected on symptoms over intermediate follow-up durations. Results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions for sustained changes in functional status.


Study Duration and Long-Term Research Gaps

The evidence base for non-prescription Naproxen Sodium primarily covers short-term research scenarios, with observation periods ranging from a single dose up to approximately seven days. Research provides an overview of what is known for these brief periods, but long-term effects are not fully established. There is limited information for long-term outcomes or the durability of symptom change after the medication is stopped. The research does not offer predictions regarding whether an individual will experience similar short-term changes over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Momendol (FAQ)

Q: How quickly does Momendol usually start to work?

A: According to official product information, the medicine is formulated as a sodium salt to promote rapid systemic absorption in the digestive tract. This formulation is designed to facilitate a quick onset of action, but regulatory documents do not typically specify a precise onset time for patient information.


Q: How long can the pain relief from Momendol be expected to last?

A: Official dosing guidelines typically recommend subsequent doses every 8 to 12 hours while symptoms persist. This dosing frequency is based on the drug's intended duration of analgesic effect.


Q: How long can Momendol be taken continuously according to product information?

A: Regulatory documents specify strict limits for self-treatment. The medicine should not be used for pain relief for more than 10 days or for fever reduction for more than 3 days, unless the user is under the specific direction of a healthcare professional.


Q: Does taking Momendol with food affect how well it works?

A: The medicine may be taken with food or milk if stomach upset occurs. However, official information notes that administration with food may delay the rate of absorption, meaning it could take longer for the effect to begin, though it does not generally change the overall amount of medicine absorbed.


Q: Is Momendol intended for chronic pain or mainly for short-term relief?

A: Momendol is officially indicated for the short-term symptomatic relief of minor aches and pains. Consistent with its non-prescription status, its use is generally focused on brief, acute episodes rather than ongoing chronic conditions.


Q: Is Momendol generally considered safe for elderly people?

A: Regulatory documents advise that older adults (65 years and over) use the lowest effective dose for the shortest duration necessary. Official guidelines include restrictions for this group because of the increased sensitivity to adverse effects.


Q: Can Momendol be taken with pain relievers that contain paracetamol/acetaminophen?

A: Authoritative public health guidance indicates that combining this medicine with paracetamol (acetaminophen) is generally acceptable for short periods as needed. Consultation with a healthcare professional is necessary for frequent or prolonged use of any combination of pain relievers.


Q: What are the most commonly reported side effects of Momendol?

A: Commonly reported adverse reactions include gastrointestinal issues such as nausea, indigestion (dyspepsia), and heartburn. Effects involving the nervous system, such as headache, dizziness, and drowsiness, are also listed among common side effects in official documents.


Q: Do regulatory agencies have warnings about long-term use of Momendol?

A: Official warnings state that the risk of serious side effects, including cardiovascular events and gastrointestinal ulceration, may increase with prolonged use. The available research evidence is primarily limited to studying short-term scenarios.


Q: Can Momendol be taken if I have a history of high blood pressure?

A: The product labeling advises that individuals with a history of high blood pressure (hypertension) should be aware that NSAIDs can affect blood pressure and potentially interfere with blood pressure medications. Professional consultation is advised prior to use.


Q: What studies exist regarding the safety profile of Momendol?

A: The official safety profile is based on clinical data and surveillance, highlighting risks common to the NSAID class. Key warnings relate to the potential for serious cardiovascular thrombotic events (like heart attack or stroke) and gastrointestinal bleeding or ulceration.


Q: Is Momendol the same as other medicines containing the same active substance?

A: All medicines with the same active ingredient and dosage are required to meet the same therapeutic quality standards. However, different brands may differ in their inactive ingredients (excipients), which are the fillers and binding agents, as well as their appearance and packaging.


Q: Is Momendol available over-the-counter or only by prescription?

A: The 220 mg dosage form of Momendol, containing naproxen sodium, is widely classified by regulatory bodies as an Over-The-Counter (OTC) Drug intended for self-treatment of minor symptoms.


Q: Does Momendol cause drowsiness or affect alertness?

A: Official documents list drowsiness and dizziness as common side effects that can occur with this medication. Users are advised to be aware of their personal reaction before driving or operating machinery.


Q: Can Momendol cause stomach upset or other digestive issues?

A: Yes, regulatory labeling lists common adverse reactions that involve the gastrointestinal system, such as dyspepsia (indigestion), heartburn, nausea, and abdominal pain.


Q: Is it possible to have an allergic reaction to Momendol?

A: Yes, the active ingredient carries an official warning of a risk of severe allergic reaction, particularly in individuals with a history of reaction to aspirin or other NSAIDs.


Q: What should I know about Momendol and its use with alcohol?

A: Official warnings note that consumption of alcohol while using the medicine is known to increase the risk of gastrointestinal bleeding. Regulatory documents state that use with alcohol is associated with increased risk, and caution is advised.


Q: Why is Momendol sometimes described as having a longer half-life than other NSAIDs?

A: The less frequent dosing, typically every 8 to 12 hours, is reflective of the medicine's longer duration of action compared to some other NSAIDs. This characteristic is supported by the pharmacological data regarding its sustained action profile.


Q: How does Momendol differ from ibuprofen, even though they are both NSAIDs?

A: The primary practical difference noted in patient-facing regulatory information is the duration of action. Naproxen Sodium (Momendol's active ingredient) is typically dosed every 8 to 12 hours, while many other common NSAIDs are dosed more frequently.


Q: Are there any food or drink restrictions while using Momendol?

A: Official warnings specifically advise against the use of the medicine when consuming three or more alcoholic drinks daily due to an increased risk of serious gastrointestinal bleeding.


Q: Is it normal to feel dizzy after taking Momendol?

A: Yes, dizziness is listed in regulatory documents as one of the commonly reported side effects of the active ingredient. As such, it is not considered an unusual occurrence for users of the medication.


Q: What does official research say about Momendol's use for joint pain?

A: The active ingredient is officially indicated for temporarily relieving minor aches and pains associated with conditions like minor pain of arthritis and muscular aches. These indications encompass forms of joint discomfort.


Q: Is there any evidence related to Momendol's use for menstrual pain?

A: Yes, regulatory documents explicitly state that the medicine is indicated for relieving minor aches and pains associated with menstrual cramps.


Q: What happens if a dose of Momendol is missed?

A: If a dose is missed, it should be taken as soon as possible. Official patient information states that the missed dose should not be taken if it is almost time for the next scheduled dose, to prevent exceeding the recommended amount.


Q: Is the active ingredient in Momendol approved for other uses besides pain relief?

A: Yes, the active ingredient is also used, in prescription forms, for the management of symptoms associated with various inflammatory and musculoskeletal conditions.


Q: Does Momendol interact with herbal supplements?

A: Official guidance advises that the safety of combining the medicine with herbal remedies and supplements is generally not established by comprehensive regulatory review. Consultation with a healthcare professional is advised when considering co-administration.


Q: Is the drug considered safe for people with asthma?

A: The drug is contraindicated (should not be used) in patients with known aspirin-sensitive asthma. Individuals with pre-existing asthma should seek professional advice before using the medicine.


Q: Can Momendol be used for fever reduction?

A: Yes, the medication is officially indicated for the temporary reduction of fever. A maximum use duration (3 days) is specified for this purpose when self-treating.


Q: Why is Momendol often mentioned in discussions about headaches or migraines?

A: The active ingredient is specifically indicated by regulatory agencies for the temporary relief of pain associated with headaches. This reflects its documented action as an effective analgesic for this common symptom.


Q: Are there specific patient groups where Momendol's side effects are more likely?

A: Official warnings note that the risk of serious side effects may be increased in certain patient groups, notably older adults (60 years and older) and those taking the drug at higher doses or for prolonged periods.


Q: Does Momendol affect the effectiveness of birth control pills?

A: Studies examining the active ingredient and some common oral contraceptives have not shown documented pharmacokinetic interactions. However, professional consultation is necessary to assess specific drug formulations.


Q: Is Momendol known by a different name in other countries?

A: Yes, the active ingredient, naproxen sodium, is marketed under a variety of different brand names worldwide. This is common practice due to regional marketing and specific regulatory approvals in each country.


Q: Can Momendol cause changes in sleep patterns?

A: Official labeling lists drowsiness as a common side effect. Additionally, warnings advise that sleeplessness (insomnia) that persists for a prolonged period may be a sign of a serious underlying condition.


Q: What is the composition of the tablets besides the active ingredient (excipients)?

A: In addition to the active ingredient, the tablets contain inactive ingredients (excipients). Official documents specifically note the inclusion of ingredients such as lactose, which is relevant information for patients with certain intolerances.

How should Momendol be stored and disposed of?

How to Store and Dispose of Momendol?

The storage and disposal of Momendol (Naproxen Sodium tablets) must adhere strictly to the conditions specified in the official regulatory labeling.

Official Storage Requirements

Condition Requirement
Temperature Store below 30 C
Protection Keep in the original package, protected from light and moisture
Safety Must be kept out of the sight and reach of children

All forms of the medicine must not be used after the expiry date printed on the packaging, as stability is not guaranteed past this point.

Disposal Instructions

To protect the environment, the official labeling mandates that Momendol must not be thrown away via wastewater or household waste. Unused or expired medicine should be disposed of by consulting a pharmacist, who can advise on local pharmaceutical waste handling programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Momendol  found in:

A-Z Index: